ID   HEC-155
AC   CVCL_2926
DR   BioSample; SAMN03151656
DR   BioSample; SAMN03472460
DR   Wikidata; Q54882257
RX   DOI=10.1007/978-4-431-53981-0_1;
RX   PubMed=2064198;
RX   PubMed=15053063;
RX   PubMed=15285295;
RX   PubMed=20143388;
CC   Problematic cell line: Contaminated. HEC-155 and HEC-180 have been shown to be identical (PubMed=20143388). Originally thought to originate from a 56 year old female patient with primary endometrial cancer.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00307.
CC   Population: Japanese.
CC   Discontinued: JCRB; JCRB1127; true.
CC   Discontinued: JCRB; NIHS0397; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): JCRB=JCRB1127
ST   Amelogenin: X
ST   CSF1PO: 9,13,14
ST   D13S317: 8
ST   D16S539: 12
ST   D5S818: 10,11
ST   D7S820: 8,11
ST   TH01: 7
ST   TPOX: 9,12
ST   vWA: 14
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_8313 ! HEC-180
SX   Female
AG   56-64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
RX   DOI=10.1007/978-4-431-53981-0_1;
RA   Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T.,
RA   Kawaguchi M.;
RT   "HEC-1 cells: establishment of an in vitro experimental system in
RT   endometrial carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo (2003).
RX   PubMed=2064198; DOI=10.1111/j.1749-6632.1991.tb37884.x;
RA   Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y.,
RA   Ohno E., Iida T.;
RT   "Establishment and characterization of human endometrial cancer cell
RT   lines.";
RL   Ann. N. Y. Acad. Sci. 622:402-421(1991).
RX   PubMed=15053063;
RA   Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.;
RT   "Quantitative study on the correlation between p53 gene mutation and
RT   its expression in endometrial carcinoma cell lines.";
RL   Eur. J. Gynaecol. Oncol. 25:55-60(2004).
RX   PubMed=15285295;
RA   Iida T., Hamano M., Yoshida N., Yonamine K., Hayashi K., Kiguchi K.,
RA   Ishizuka B., Nishimura Y., Arai T., Kawaguchi M., Hata H.,
RA   Watanabe J., Kuramoto H.;
RT   "Establishment and characterization of two cell lines (HEC-155, HEC-180)
RT   derived from uterine papillary serous adenocarcinoma.";
RL   Eur. J. Gynaecol. Oncol. 25:423-427(2004).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).